BI-1808 clinical trials

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

This study is testing a new drug, BI-1808, by itself and with another medicine, pembrolizumab (Keytruda®), for people with advanced cancers. The goal is to see how safe the new drug is, what side effects it causes, and find the right dose for future studies.